Research programme: chemokine receptor antagonists - Sanofi
Alternative Names: AMD 887; CXCR4 antagonists - SanofiLatest Information Update: 31 Mar 2022
At a glance
- Originator Genzyme Corporation
- Developer Sanofi
- Class
- Mechanism of Action CCR5 receptor antagonists; CXCR4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma; Cancer; HIV infections; Rheumatoid arthritis